Finally, three clinical trials are ongoing for patients with STS, one based on enoblituzumab, one using B7-H3 specific CAR T cells and the last using a bi-specific molecule which targets B7-H3 and CD3 (www.clinicaltrials.gov, accessed on 28 March 2021). Here, CD276 is linked to telomere syndrome.